Stifel Financial Corp Cuts Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Stifel Financial Corp trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 41.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,269 shares of the company's stock after selling 16,643 shares during the quarter. Stifel Financial Corp owned approximately 0.07% of Medpace worth $7,767,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Sequoia Financial Advisors LLC boosted its holdings in shares of Medpace by 21.3% during the second quarter. Sequoia Financial Advisors LLC now owns 603 shares of the company's stock worth $248,000 after purchasing an additional 106 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Medpace by 106.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 1,343 shares of the company's stock worth $553,000 after buying an additional 694 shares during the period. Blue Trust Inc. grew its position in shares of Medpace by 40.6% in the 2nd quarter. Blue Trust Inc. now owns 561 shares of the company's stock worth $227,000 after buying an additional 162 shares during the last quarter. Raymond James & Associates increased its stake in shares of Medpace by 13.1% during the second quarter. Raymond James & Associates now owns 54,735 shares of the company's stock valued at $22,543,000 after buying an additional 6,351 shares during the period. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Medpace by 6.9% during the second quarter. Nisa Investment Advisors LLC now owns 1,011 shares of the company's stock valued at $416,000 after acquiring an additional 65 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Down 0.4 %

Shares of Medpace stock traded down $1.50 during trading hours on Friday, reaching $345.93. 275,170 shares of the stock traded hands, compared to its average volume of 282,165. Medpace Holdings, Inc. has a one year low of $277.72 and a one year high of $459.77. The firm has a market capitalization of $10.75 billion, a price-to-earnings ratio of 30.22, a P/E/G ratio of 1.89 and a beta of 1.37. The company has a 50 day moving average price of $339.14 and a 200 day moving average price of $368.27.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million during the quarter, compared to analysts' expectations of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business's quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.22 earnings per share. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

MEDP has been the topic of several research analyst reports. TD Cowen reduced their price target on shares of Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a research report on Wednesday, October 23rd. Baird R W cut Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. UBS Group downgraded Medpace from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $420.00 to $350.00 in a report on Friday, September 27th. Redburn Atlantic began coverage on shares of Medpace in a report on Monday, October 14th. They set a "buy" rating and a $404.00 target price on the stock. Finally, Robert W. Baird increased their price target on shares of Medpace from $349.00 to $354.00 and gave the stock a "neutral" rating in a research note on Monday, November 25th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $380.56.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.